UniProtKB/Swiss-Prot Q92560: Variant p.Cys91Ser

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 91 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Cysteine (C) to Serine (S) at position 91 (C91S, p.Cys91Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from medium size and polar (C) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In KURIS; loss-of-function variant; increased steady-state level of ubiquitinated H2A are found in patient cells; unable to rescue impaired H2AK119ub deubiquitination when expressed in BAP1-deficient cells; abolishes deubiquitinase activity; does not affect its ability to interfere with BRCA1 E3 ligase activity; does not affect localization to the nucleus; has a dominant negative effect on cell growth; does not affect interaction with FOXK1 and FOXK2; has no effect on PR-DUB complex assembly; unable to activate transcription. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs1559591264 [ dbSNP | Ensembl ]

Sequence information

Variant position: 91 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 729 The length of the canonical sequence.
Location on the sequence: VIDDDIVNNMFFAHQLIPNS C ATHALLSVLLNCSSVDLGPT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 729	Ubiquitin carboxyl-terminal hydrolase BAP1
Domain	4 – 235	UCH catalytic
Active site	91 – 91	Nucleophile
Site	85 – 85	Transition state stabilizer
Mutagenesis	91 – 91	C -> A. Abolishes deubiquitinase activity. Has no effect on interaction with HCFC1.
Helix	91 – 101

Literature citations

BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.
Nishikawa H.; Wu W.; Koike A.; Kojima R.; Gomi H.; Fukuda M.; Ohta T.;
Cancer Res. 69:111-119(2009)
Cited for: FUNCTION; INTERACTION WITH BARD1 AND BRCA1; CHARACTERIZATION OF VARIANT KURIS SER-91; The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1.
Machida Y.J.; Machida Y.; Vashisht A.A.; Wohlschlegel J.A.; Dutta A.;
J. Biol. Chem. 284:34179-34188(2009)
Cited for: FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH HCFC1; MUTAGENESIS OF 363-ASN--TYR-366; CHARACTERIZATION OF VARIANT KURIS SER-91; The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression.
Yu H.; Mashtalir N.; Daou S.; Hammond-Martel I.; Ross J.; Sui G.; Hart G.W.; Rauscher F.J. III; Drobetsky E.; Milot E.; Shi Y.; Affar el B.;
Mol. Cell. Biol. 30:5071-5085(2010)
Cited for: FUNCTION; IDENTIFICATION IN THE PR-DUB COMPLEX; INTERACTION WITH YY1 AND HCFC1; IDENTIFICATION BY MASS SPECTROMETRY; CHARACTERIZATION OF VARIANT KURIS SER-91; BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes.
Okino Y.; Machida Y.; Frankland-Searby S.; Machida Y.J.;
J. Biol. Chem. 290:1580-1591(2015)
Cited for: FUNCTION; INTERACTION WITH FOXK1 AND FOXK2; PHOSPHORYLATION AT THR-493; MUTAGENESIS OF SER-489; SER-492; THR-493 AND THR-495; CHARACTERIZATION OF VARIANT KURIS SER-91; Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder.
Kuery S.; Ebstein F.; Molle A.; Besnard T.; Lee M.K.; Vignard V.; Hery T.; Nizon M.; Mancini G.M.S.; Giltay J.C.; Cogne B.; McWalter K.; Deb W.; Mor-Shaked H.; Li H.; Schnur R.E.; Wentzensen I.M.; Denomme-Pichon A.S.; Fourgeux C.; Verheijen F.W.; Faurie E.; Schot R.; Stevens C.A.; Smits D.J.; Barr E.; Sheffer R.; Bernstein J.A.; Stimach C.L.; Kovitch E.; Shashi V.; Schoch K.; Smith W.; van Jaarsveld R.H.; Hurst A.C.E.; Smith K.; Baugh E.H.; Bohm S.G.; Vyhnalkova E.; Ryba L.; Delnatte C.; Neira J.; Bonneau D.; Toutain A.; Rosenfeld J.A.; Audebert-Bellanger S.; Gilbert-Dussardier B.; Odent S.; Laumonnier F.; Berger S.I.; Smith A.C.M.; Bourdeaut F.; Stern M.H.; Redon R.; Krueger E.; Margueron R.; Bezieau S.; Poschmann J.; Isidor B.;
Am. J. Hum. Genet. 109:361-372(2022)
Cited for: VARIANTS KURIS ALA-12; THR-12; LYS-31; PRO-49; ARG-91; GLY-91; SER-91; ARG-169 AND GLN-718; CHARACTERIZATION OF VARIANTS KURIS THR-12; ARG-91; SER-91; ARG-169 AND GLN-718; INVOLVEMENT IN KURIS; FUNCTION; SUBCELLULAR LOCATION;